Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: inoue k. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K. Nogami N, et al. Among authors: inoue k. Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8. Lung Cancer. 2015. PMID: 25534129 Clinical Trial.
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K. Kudo K, et al. Among authors: inoue k. Cancer Chemother Pharmacol. 2016 May;77(5):1005-9. doi: 10.1007/s00280-015-2910-9. Epub 2016 Mar 31. Cancer Chemother Pharmacol. 2016. PMID: 27029623
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Oda N, et al. Among authors: inoue m, inoue k. Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9. Clin Lung Cancer. 2017. PMID: 27506489 Clinical Trial.
Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Kawano Y, et al. Among authors: inoue k. Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18. Lung Cancer. 2018. PMID: 30429011 Clinical Trial.
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: inoue k. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Tsuchiya-Kawano Y, et al. Among authors: inoue k. Oncologist. 2020 Jun;25(6):475-e891. doi: 10.1634/theoncologist.2019-0746. Epub 2019 Oct 24. Oncologist. 2020. PMID: 31649134 Free PMC article. Clinical Trial.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: inoue k. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
9,848 results